slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 1,471-1,500
Pages 885
Rows per page 30
Arc
1,471-1,500 of 26,550
13
The slide uses a third-party study (Yang et al., 2015) to support the claim of a superior therapeutic index for R-ketamine.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
14
The slide contrasts the therapeutic benefit (MADRS) with the lack of side effects (CADSS) compared to S-Ketamine benchmarks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
15
CADSS = Clinician administered dissociative states scale. Data points are clustered by time interval.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
16
The slide uses a standard clinical trial flow diagram (randomization to treatment arms).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
17
The slide uses a comparison structure to contrast safety/tolerability goals against efficacy goals.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
18
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
19
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
20
The chart compares 25mg, 10mg, and 1mg (comparator) dosages. Statistical significance is marked with asterisks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
21
The slide outlines the study arms, randomization ratios, and primary endpoint timing for two distinct clinical trials.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
22
The slide uses a list of three key regulatory takeaways followed by a forward-looking implication for the pipeline.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
23
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
24
The slide introduces the drug candidate VLS-01, providing its chemical identity and current clinical trial status.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
25
The chart displays statistical significance markers (p-values) at Day 1, Day 2, and Day 7.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
26
The slide uses a process flow diagram to represent clinical trial cohorts and SMG (Safety Monitoring Group) review gates.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
27
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
28
The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
30
Slide 30. Includes statistical significance markers (*, **, ***).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
31
The slide uses topographical brain maps to visualize EEG data changes. Significant channels are marked with black circles.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
32
Slide 32 of a presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
33
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
34
The slide uses a vertical process flow to show the progression from pre-clinical to clinical phases, mapped against key de-risking milestones.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
35
The slide uses a grouped bar chart to show T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage groups.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
36
Includes study design diagram and assessment schedule table.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
37
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
38
The slide uses a chemical structure diagram to establish the scientific basis for the product.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
39
The slide outlines two distinct clinical study parts: a Single Ascending Dose (SAD) study and a crossover comparator study.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
40
ATAI | Investor Presentation Deck | 41 slidesATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done2 hits
05
Blue Water Vaccines | Results Presentation Deck | 15 slidesBlue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
06
The slide describes the mechanism of action for a specific vaccine candidate (BHN97ΔftsY).Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · AgitateLoop · Jobs To Be Done2 hits